Canada’s first Stelara (ustekinumab) biosimilar has been introduced to the market by Alvotech and marketing partner Jamp Pharma through the latter’s BioJamp unit. The launch comes after the firms received approval from Health Canada towards the end of 2023. (Also see "Alvotech Notches Up Another Stelara Biosimilar Approval – In Canada" - Generics Bulletin, 14 November, 2023.).
Alvotech And Jamp Launch First Stelara Biosimilar In Canada
Jamteki Version Of Ustekinumab Introduced By Jamp Is Country’s First Stelara Rival
Alvotech and Jamp have launched Canada’s first Stelara biosimilar, just a couple of weeks after Alvotech disclosed a settlement that would allow its ustekinumab product to be introduced in markets around the world.
More from Biosimilars
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
More from Products
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.